Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial
Why the study?
Does ticagrelor reduce the composite of cardiovascular death, myocardial infarction, and stroke compared to clopidogrel in patients with acute coronary syndrome intended for non-invasive management?
Population
5,216 patients admitted to hospital for acute coronary syndrome who were specified as planned for…
Comparison
Ticagrelor vs Clopidogrel
Design
RCT, Randomised treatment
Follow-up
one year
Authors
Discussion
Loading...
Member takes
Implication
Supports ticagrelor over clopidogrel in noninvasively managed ACS; extends PLATO consistency to this population.
Structured PICO
Does ticagrelor reduce the composite of cardiovascular death, myocardial infarction, and stroke compared to clopidogrel in patients with acute coronary syndrome intended for non-invasive management?
P
Population
5,216 patients admitted to hospital for acute coronary syndrome who were specified as planned for non-invasive management (28% of the 18,624 patients in the PLATO trial), across 862 centres in 43 countries.
I
Intervention
Ticagrelor
C
Comparator
Clopidogrel
O
Outcome
Primary composite end point of cardiovascular death, myocardial infarction, and stroke during one yearcomposite
In patients with acute coronary syndrome intended for non-invasive management, ticagrelor significantly reduces the composite of cardiovascular death, myocardial infarction, and stroke compared to clopidogrel, consistent with the overall PLATO trial results.
Cite This Study
James et al. (2011) studied this question.